华润双鹤药业股份有限公司 关于召开2025年第一季度业绩说明会的公告

Core Viewpoint - The company, China Resources Double Crane Pharmaceutical Co., Ltd., is set to hold a performance briefing for the first quarter of 2025 on April 30, 2025, to discuss its financial results and address investor inquiries [2][3]. Group 1: Performance Briefing Details - The performance briefing will take place on April 30, 2025, from 9:30 AM to 10:30 AM [3]. - The briefing will be conducted via the Shanghai Stock Exchange Roadshow Center's online platform [2][3]. - Investors can submit questions for the briefing from April 23 to April 29, 2025, through the Roadshow Center website or via email [4]. Group 2: GMP Compliance Announcement - The company's subsidiary, China Resources Zizhu Pharmaceutical Co., Ltd., has received a GMP compliance notice for its Diquafosol Sodium Eye Drops, indicating adherence to production quality management standards [7][8]. - The GMP inspection was conducted from March 12 to March 14, 2025, and the production capacity for the eye drops is 80 million bottles per year [8]. - The global sales of Diquafosol Sodium Eye Drops reached $161.3 million in 2023, with the Chinese market generating sales of 228 million RMB [9]. Group 3: Vitamin B6 Injection Approval - The subsidiary, China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd., has received approval for its Vitamin B6 injection after passing the consistency evaluation [12][14]. - The Vitamin B6 injection is used for treating Vitamin B6 deficiency and related conditions, with a total market sales of 453 million RMB in 2023 [15]. - The company invested approximately 3.89 million RMB in the research and development of the Vitamin B6 injection [14].